Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (2179)	8/11/2003 9:13:22 AM
From: Icebrg	Respond to of 2243

Quid No, I have no idea really what type of person he is. He strikes me as someone like for example Paul Freiman of NTTI. I.e a seasoned executive who takes care of a small company - not because he has to, but because he likes the challenge. Until he left Ohmeda his career seems rather solid. After that it gives a very restless impression. Ohmeda was bought by Finnish (!) Instrumentarium (who is now the subject of a courtship from GE). Considering the circumstances I guess that Dr. Stoll didn't leave Ohmeda as a poor man. His involvement with Cortex actually started at the Board level. He got his place there in April and in August he suddenly became CEO after the previous CEO had been booted. I believe that Vince Simmons did a fairly good job with the company (considering the circumstances) but that he left the company too exposed financially. I don't think his replacement was a part of Plan A, but after Shire returned the rights to CX516 in the ADHD-indication, the company suddenly was virtually cashless. Simmons had counted on being able to extract some funding from Shire one way or another. Stoll's recruitment to the board of Cortex seems to have a lot to do with Messrs Casamento and Allnut. They all three sit on the board of Questcor, where Casamento is also CEO and chairman. Allnut used to be the chairman of Cortex (although he is a NASA-man), but stepped down when Stoll became CEO (and chairman). Casamento and Stoll also see each other in the boardroom of LifePoint Inc. I think that what he has done so far and what he says, that he intends to do makes a lot of sense. My impression is good. The only negative thing I can say about him is that he was very generous when options were "rewarded" at the annual meeting. On the other hand - if he can make something out of this company, he has no doubt deserved it. As a curiosity you might have noticed Joann Data (Amylin) as a part-time management person. And the fact that they managed to engage Arvid Carlsson as a scientific advisor is impressive (the same thing can be said about Mr Carlsson - perhaps he is helping himself to some Ampakines). Erik